Skip to main content

LCD L38809: Botulinum Toxins

LCD L38809, Botulinum Toxins, is the Local Coverage Determination that Novitas Solutions, Inc. applies to claims from 11 states plus DC (AR, CO, DC, DE, LA, MD, MS, NJ and others), effective 2025-11-09 and first in force 2021-03-21. The policy text runs 805 words, and its billing and coding article A58423 lists 103 ICD-10-CM codes that support medical necessity for 5 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 103 covered ICD-10-CM codes: the same total as L33274 (First Coast Service Options, Inc., 103 codes, revised 2025-11-09).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Novitas Solutions, Inc.
States and territories
12
AR CO DC DE LA MD MS NJ NM OK PA TX
Revision effective
2025-11-09
Original effective
2021-03-21
Policy text
805 words
Covered ICD-10 codes (articles)
103

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38809
ContractContractorTypeStates
12101Novitas Solutions, Inc.A and B MACDE
12201Novitas Solutions, Inc.A and B MACDC
12301Novitas Solutions, Inc.A and B MACMD
12401Novitas Solutions, Inc.A and B MACNJ
12501Novitas Solutions, Inc.A and B MACPA
12102Novitas Solutions, Inc.A and B MACDE
12202Novitas Solutions, Inc.A and B MACDC
12302Novitas Solutions, Inc.A and B MACMD
12402Novitas Solutions, Inc.A and B MACNJ
12502Novitas Solutions, Inc.A and B MACPA
12901Novitas Solutions, Inc.A and B MACDC DE MD NJ PA
07102Novitas Solutions, Inc.A and B MACAR
07202Novitas Solutions, Inc.A and B MACLA
07101Novitas Solutions, Inc.A and B MACAR
07201Novitas Solutions, Inc.A and B MACLA
07301Novitas Solutions, Inc.A and B MACMS
07302Novitas Solutions, Inc.A and B MACMS
04111Novitas Solutions, Inc.A and B MACCO
04211Novitas Solutions, Inc.A and B MACNM
04311Novitas Solutions, Inc.A and B MACOK
04411Novitas Solutions, Inc.A and B MACTX
04112Novitas Solutions, Inc.A and B MACCO
04212Novitas Solutions, Inc.A and B MACNM
04312Novitas Solutions, Inc.A and B MACOK
04412Novitas Solutions, Inc.A and B MACTX
04911Novitas Solutions, Inc.A and B MACCO NM OK TX

Billing and coding article A58423: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58423 (Billing and Coding: Botulinum Toxins) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A58423: Billing and Coding: Botulinum Toxins (Billing and Coding, effective 2025-11-09)

Covered ICD-10-CM codes
103
5 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
5
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A58423
ICD-10-CMDescription (FY2027)
F95.1Chronic motor or vocal tic disorder
F95.2Tourette's disorder
G11.4Hereditary spastic paraplegia
G24.3Spasmodic torticollis
G24.4Idiopathic orofacial dystonia
G24.5Blepharospasm
G24.8Other dystonia
G25.0Essential tremor
G43.701Chronic migraine without aura, not intractable, with status migrainosus
G43.709Chronic migraine without aura, not intractable, without status migrainosus
G43.711Chronic migraine without aura, intractable, with status migrainosus
G43.719Chronic migraine without aura, intractable, without status migrainosus
G43.E01Chronic migraine with aura, not intractable, with status migrainosus
G43.E09Chronic migraine with aura, not intractable, without status migrainosus
G43.E11Chronic migraine with aura, intractable, with status migrainosus
G43.E19Chronic migraine with aura, intractable, without status migrainosus
G51.31Clonic hemifacial spasm, right
G51.32Clonic hemifacial spasm, left
G51.33Clonic hemifacial spasm, bilateral
G80.0Spastic quadriplegic cerebral palsy
G80.1Spastic diplegic cerebral palsy
G80.2Spastic hemiplegic cerebral palsy
G80.8Other cerebral palsy
G81.11Spastic hemiplegia affecting right dominant side

Procedure codes: J0585 (Injection, onabotulinumtoxina, 1 unit), J0586 (Injection, abobotulinumtoxina, 5 units), J0587 (Injection, rimabotulinumtoxinb, 100 units), J0588 (Injection, incobotulinumtoxin a, 1 unit), J0589 (Injection, daxibotulinumtoxina-lanm, 1 unit).

Coverage indications, limitations and medical necessity

Clostridium botulinum toxin describes a family of neurotoxins produced by the anaerobic bacteria of the species C botulinum. There are 7 distinct serotypes of botulinum toxin: A, B, C, D, E, F, and G. All botulinum neurotoxin serotypes are understood to produce their clinical effect by blocking the release of the neurotransmitters, principally acetylcholine, from nerve endings. 1 There are 5 distinct serotype A botulinum toxin products, onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA-xvfs (Jeuveau), and daxibotulinum toxin A (Daxxify) and 1 serotype B botulinum toxin product, rimabotulinumtoxinB (Myobloc) that have been approved by the FDA. PrabotulinumtoxinA-xvfs (Jeuveau) is indicated for cosmetic use only. 2

Whether a botulinum toxin is produced from the same or different serotype producing strain, they undergo different manufacturing processes which yield differences in the size and weight of the molecules. Because of this, Botox, Dysport, Xeomin, Myobloc, and Daxxify, as well as other botulinum toxin products available internationally, are not interchangeable. They are chemically, pharmacologically, and clinically distinct. 1

For the purposes of this LCD, botulinum toxin injections (BTI) refers to the general use of these products as a whole. Each specific product will be discussed by name. BTI are commonly used to treat a wide variety of conditions in which the main therapeutic effect is to decrease undesired or excessive contraction of striated or smooth muscle. They produce a presynaptic neuromuscular blockade by preventing the release of acetylcholine from the nerve endings. 1 The resulting chemical denervation of muscle produces local paresis or paralysis and allows individual muscles to be weakened selectively.

Covered Indications

NOTE: The 5 botulinum therapies are not interchangeable and are only covered as listed below.

Botulinum toxins (Botox, Dysport, Xeomin, Myobloc, and Daxxify), will be considered reasonable and necessary when administered for treatment of FDA-labeled indications and off-label indications (as applicable) below:

• FDA indications for onabotulinumtoxinA (Botox) as noted on the FDA website: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103000 3

• Off-Label indications for onabotulinumtoxinA (Botox) are considered reasonable and necessary in patients for the following conditions:

• Esophageal achalasia in the following circumstances:

• Medically high-risk patients who cannot undergo other invasive treatments (peroral endoscopic myotomy [POEM], Heller myotomy, pneumatic dilation [PD]) 4-12

• As a bridge for those awaiting more effective treatments such as Heller myotomy, PD, or POEM 10

• During work-up and treatment planning of definitive treatments for achalasia 13,14

• Chronic anal fissure for patients with inadequate response to conservative or pharmacologic treatment 15

• Essential hand tremor for patients with a high amplitude tremor that disrupts activities of daily living and have had inadequate response to oral pharmacotherapy such as propranolol and primidone 16

• Focal hand and limb dystonia 16

• Hemifacial spasm in adults (cranial nerve VII disorder) 16

• Isolated oromandibular dystonia (also known as orofacial dystonia, isolated oromandibular dystonia, oromandibular dystonia, blepharospasm associated with orofacial dystonia, and Meige syndrome) in adults 17

• Laryngeal dystonia (spastic dysphonia) for adductor type (ADSD) 16

• Bothersome simple motor tics in adolescents and adults when the benefits of treatment outweigh the risks 18

• Severely disabling or aggressive vocal tics in older adolescents and adults when the benefits of treatment outweigh the risks 18

• FDA indications for abobotulinumtoxinA (Dysport) as noted on the FDA website: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125274 19

• Off-label indications for abobotulinumtoxinA (Dysport) are considered reasonable and necessary in patients for the following conditions:

• Blepharospasm in adults 16,17

• Hemifacial spasm in adults (cranial nerve VII disorder) 16

• Isolated oromandibular dystonia (also known as orofacial dystonia, isolated oromandibular dystonia, oromandibular dystonia, blepharospasm associated with orofacial dystonia, and Meige syndrome) in adults 17

• FDA indications for incobotulinumtoxinA (Xeomin) as noted on the FDA website: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125360 20

• FDA indications for rimabotulinumtoxinB (Myobloc) as noted on the FDA website: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103846 21

• FDA indications for daxibotulinumtoxinA-lanm (Daxxify) as noted on the FDA website: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761127 . 22

Limitations

• Localization procedures would not be expected and therefore considered not reasonable and necessary for easily targeted muscles. 17,23

• Administration of onabotulinumtoxinA (Botox) for achalasia in the following circumstances is considered not reasonable and necessary:

• Patients with contraindications for Botox or upper endoscopy. 24

• Injection of botulinum toxin in the esophageal body. 6,8-10

• Treatment of isolated lower limb dystonia and isolated exercise-associated lower limb dystonia is considered not reasonable and necessary. 25

• Treatment of abductor spasmodic dysphonia is considered not reasonable and necessary. 26

• Treatment of wrinkles, also called glabellar lines, smoker’s lines, crow’s feet, laugh lines, and aging neck, using botulinum toxins, are considered cosmetic procedures and not covered under Medicare.

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

Summary of evidence (opening)

Off-Label Indications Supported by Evidence-Based Guidelines

Botulinum toxin is used therapeutically to reduce pathologic muscle contraction. Health outcomes of interest are improved function and improved quality of life.

The American Academy of Neurology (AAN) has produced a clinical practice guideline process manual that includes a discussion regarding elements of recommendations and levels of evidence (see tables below). 27

Level (Quality) of Evidence

The contractor cites 235 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2021-03-21
Current revision effective
2025-11-09
MCD version
30

Other related documents: A60163 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Novitas Solutions, Inc. hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

Prior authorization in Original Medicare

  • Hospital outpatient departments need prior authorization nationwide for dates of service on or after July 1, 2020; it is a condition of payment for the hospital claim and related claims. CMS service group: Botulinum toxin injections. Codes on the CMS list: 64612, 64615, J0585, J0586, J0587 and J0588.
  • Ambulatory surgical centers in the CMS prior authorization demonstration: January 19, 2026 in California, Florida, Georgia, Maryland, New York, Pennsylvania and Tennessee; February 16, 2026 in Arizona, Ohio and Texas; requests are voluntary, and claims without one go to pre-payment review. CMS service group: Botulinum toxin injections. Codes on the CMS list: 64612, 64615, J0585, J0586, J0587, J0588 and J0589.

Medicare Advantage plans run their own prior authorization lists. See the services and codes on the Medicare prior authorization list.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38809 cover?

Clostridium botulinum toxin describes a family of neurotoxins produced by the anaerobic bacteria of the species C botulinum. There are 7 distinct serotypes of botulinum toxin: A, B, C, D, E, F, and G. All botulinum neurotoxin serotypes are understood to produce their clinical effect by blocking the release of the neurotransmitters, principally acetylcholine, from nerve endings. 1 There are 5 distinct serotype… The full 805-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38809 apply to?

Novitas Solutions, Inc. applies it to Medicare claims in 11 states plus DC: AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38809?

The companion billing and coding article A58423 lists 103 ICD-10-CM codes in 5 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L38809?

A denial under LCD L38809 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58423's 103 covered diagnosis codes, then file a redetermination with Novitas Solutions, Inc. within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.